Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Subscribe To Our Newsletter & Stay Updated
